Top 10 Pharma Manufacturing Companies In India 2026: Powering Global Healthcare

In 2026, India's hold on the title "Pharmacy of the World" has never been stronger. The Indian pharmaceutical market stood at approximately US$55 billion in 2025 and is projected to reach US$120–130 billion by 2030. Pharma exports hit US$30.47 billion in FY2024–25, and India supplies generic medicines to over 200 countries. Budget 2026–27's ₹10,000 crore Biopharma Shakti programme signals clearly that the next phase of Indian pharma isn't about volume alone — it's about value.

Rankings below are by market capitalisation, sourced from BSE/NSE data as of May 2026. Figures are indicative and change daily. This article is for informational purposes only and does not constitute financial or investment advice.

1. Sun Pharmaceutical Industries Ltd.

Est. 1983 

Headquarters: Mumbai 

Market Cap (May 2026): ~₹4.43 lakh crore

India's largest pharma company by market cap and domestic prescription share. FY26 revenue grew 11.9% to ₹58,462 crore; net profit rose 5% to ₹11,479 crore. Innovative medicines crossed US$1 billion in FY26, anchored by psoriasis drug Ilumya (+17%). 

In May 2026, Sun signed a definitive agreement to acquire Organon & Company for US$11.75 billion, a transformative move in support of its global speciality ambitions. Domestic market share reached 8.4%, the highest since the Ranbaxy acquisition. R&D runs at ~6% of revenue, backed by ~1,600 patents.

2. Divi's Laboratories Limited

Est. 1990 

Headquarter: Hyderabad 

Market Cap (May 2026): ~₹1.82 lakh crore

India's foremost pure-play API and custom synthesis company, supplying originator and generic companies across 95+ countries. Divi's manufactures active ingredients for other companies' medicines rather than selling its own brands, a model that commands premium margins. Q3 FY26 revenue grew 25% to ₹2,319 crore; PAT jumped 65% to ₹589 crore. Its greenfield Kakinada Unit-III is progressively adding capacity. Manufacturing sites in Hyderabad and Visakhapatnam hold USFDA, UK MHRA, and other major regulatory approvals.

3. Torrent Pharmaceuticals Ltd.

Est. 1959 

Headquarters: Ahmedabad 

 Market Cap (May 2026): ~₹1.52 lakh crore

The first Indian company to achieve the highest prescription market share in both Germany and Brazil. Torrent has built a strong branded generics business in cardiovascular, CNS, GI, and women's health across 50+ countries. 

Acquisitions: Elder Pharma's Indian brands, Unichem's domestic portfolio, and Pfizer's German subsidiary give it a durable multi-geography presence. In 2026, Torrent entered the semaglutide market in India via a licensing deal with Zydus, and the stock delivered a 39.1% one-year return.

4. Cipla Ltd.

Est. 1935 

Headquarters: Mumbai

Market Cap (May 2026): ~₹1.13 lakh crore

With nine decades of history, Cipla manufactures 1,500+ products across 65+ therapeutic categories in 80+ countries and is the third-largest player in India's private prescription market. Its role in making antiretrovirals affordable for HIV patients in Africa remains a landmark in access to medicine. Cipla declared a ₹13 per share dividend for Q4 FY26, is expanding its respiratory and oncology pipelines, and remains almost debt-free.

5. Mankind Pharma Ltd.

Est. 1995 

Headquarters: New Delhi 

Market Cap (May 2026): ~₹85,000–90,000 crore

One of India's largest pharma companies by domestic sales, with deep penetration in Tier 2 and Tier 3 cities. Its portfolio spans acute and chronic therapies alongside consumer healthcare products covering antacids, contraceptives, pregnancy tests, and supplements. Mankind holds 300+ patent filings (85 granted) and 2,319+ trademarks. 

Phase 1 trials for a novel anti-diabetic molecule are complete, a biosimilars pipeline is in development, and the company has launched India's first patient-centric sustainable packaging.

6. Dr. Reddy's Laboratories Ltd.

Est. 1984 

Headquarter: Hyderabad 

Market Cap (May 2026): ~₹1.05 lakh crore

A global generics and biosimilars company in 76 countries, recognised with Gold Medal status by EcoVadis for sustainability. Dr Reddy's filed 12 first-to-file ANDAs in the US for FY2026 patent expiries and was among the first to receive Indian approval for a semaglutide generic. AI and IoT are being integrated into manufacturing and data operations. Key therapy areas include oncology, cardiovascular, GI, and dermatology.

7. Lupin Limited

Est. 1968 

Headquarters: Mumbai 

Market Cap (May 2026): ~₹1.00 lakh crore

Lupin operates across 100+ countries through 15 manufacturing facilities and 7 R&D centres, and is the world's largest supplier of anti-TB APIs. It entered the semaglutide market in 2026 via a licensing deal with Zydus for its reusable pen and is one of the few Indian pharma companies building patient-facing digital health tools, the Lyfe app for cardiac rehabilitation. The stock hit new 52-week highs in May 2026.

8. Zydus Lifesciences Ltd.

Est. 1952 

Headquarters: Ahmedabad 

Market Cap (May 2026): ~₹90,000 crore

Formerly Cadila Healthcare, Zydus is a fully integrated pharma company with 26,000+ employees and plants across six Indian states. In 2026, it received final USFDA approval for generic Eltrombopag tablets and was one of the first companies approved for semaglutide in both diabetes and obesity indications in India, licensing its reusable pen technology to Lupin and Torrent. Its pipeline is anchored in biologics, biosimilars, vaccines, and complex generics, including monoclonal antibodies and peptides.

9. Aurobindo Pharma Limited

Est. 1986 

Headquarter: Hyderabad 

Market Cap (May 2026): ~₹69,000 crore

Aurobindo exports to 150+ countries through 27 global manufacturing and packing facilities, 11 API units and 15 formulation units, with approvals from USFDA, UK MHRA, and other major regulators. FY2025 revenue was ₹31,724 crore (~US$3.8 billion). The company also operates AuroZymes, a biocatalyst division for pharmaceutical and chemical industry clients. Strategic expansion is underway in oncology, respiratory, hormonal, and biosimilar segments.

10. Alkem Laboratories Ltd.

Est. 1973 

Headquarters: Mumbai 

Market Cap (May 2026): ~₹69,000 crore

Alkem sells across 40+ countries through 19 manufacturing units and has filed 125+ ANDAs with the USFDA. Its product range covers anti-infectives, gastroenterology, dermatology, urology, and OTC drugs in a full range of dosage forms. All key manufacturing sites hold US FDA, UK MHRA, TGA (Australia), and WHO approvals. Alkem was among the first wave of Indian companies to launch a branded generic semaglutide in India in 2026, demonstrating the commercial agility that has consistently kept it in the top 10.

Three Companies Gaining Ground in 2026

The market cap ranking tells only part of the story. Three companies outside the top 10 are reshaping Indian pharma in ways the numbers don't yet fully reflect.

Biocon (~₹69,496 crore market cap, up 29.4% year-on-year) is India's only large-cap biosimilars specialist and arguably the most strategically significant company not yet in the top 10. In FY26, its biosimilars business grew revenue 16% and EBITDA 40%, on a like-for-like basis.

With 20+ biosimilars across insulins, monoclonal antibodies, and oncology biologics, and a top-five global position in the category, Biocon is a primary beneficiary of Budget 2026–27's Biopharma Shakti programme. At its current trajectory, a top 10 entry within 1–2 years is plausible.

Laurus Labs (~₹50,000–55,000 crore) is the CDMO story the industry needs. The stock rallied over 80% in 2025, its best year in five, driven by a 50-million-vial oncology injectables plant opened in 2024 and growing demand from global pharma companies diversifying away from China. Motilal Oswal and Jefferies both carry Buy ratings on the stock.

Piramal Pharma completes the trio as a contract manufacturing and CDMO player, gaining analyst attention. HDFC Securities initiated coverage with a Buy rating in January 2026, grouping Piramal with Divi's and Laurus as the best positioned to capture incremental outsourcing from multinationals.

Conclusion

India's pharmaceutical sector in 2026 is bigger, faster, and more diversified than any ranking alone captures. The top 10, led by Sun Pharma's Organon acquisition and Zydus's semaglutide momentum, represent the established engine. Biocon, Laurus Labs, and Piramal Pharma show where the next wave is heading: biosimilars, biologics, and high-value contract manufacturing. 

Together, these pharma manufacturing companies in India are making the US$130 billion market target by 2030 look very achievable.

FAQs

1. Which is the No. 1 pharmaceutical company in India? 

Sun Pharmaceutical Industries Ltd., with a market cap of ~₹4.43 lakh crore and an 8.4% domestic prescription market share as of March 2026, is India's largest pharma company by both metrics.

2. What are the top 5 pharma companies in India in 2026? 

By market cap: Sun Pharma, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, and Dr. Reddy's Laboratories. Note that Lupin and Dr Reddy's have swapped positions in recent months as market values shift.

3. How big is India's pharmaceutical industry? 

The Indian pharmaceutical market stood at ~US$55 billion in 2025 (Bain & Co./IBEF) and is projected to reach US$120–130 billion by 2030. Pharma exports were US$30.47 billion in FY2024–25.

4. What makes Indian pharma globally competitive? 

Cost-effective manufacturing, a large, skilled scientific workforce, deep generic and API expertise, strong regulatory compliance (USFDA, WHO, EU), and a growing pipeline in biosimilars and speciality medicines.

5. What is semaglutide, and why does it matter for Indian pharma? 

Semaglutide is the active ingredient in Ozempic and Wegovy. Following patent expiry in India on 20 March 2026, around 10 Indian companies launched branded generics. Nomura Research estimates this could become a ₹12,000 crore market over five years, one of the largest generic opportunities in recent Indian pharma history.